iECURE
About:
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Website: http://iecure.com
Top Investors: Novo Holdings, OrbiMed, Versant Ventures, LYFE Capital
Description:
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Total Funding Amount:
$115M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Philadelphia, Pennsylvania, United States
Founded Date:
2012-01-01
Founders:
Jim Wilson
Number of Employees:
251-500
Last Funding Date:
2022-11-30
IPO Status:
Private
Industries:
© 2025 bioDAO.ai